Furthermore, the previous study showed that the RNPN treatment ameliorates nonalcoholic steatohepatitis NASH fibrosis via the decrease of hepatic stellate cell activation marker of alpha-smooth muscle actin (α-SMA) [44]. This evidence concerns the gene ACTA1 and metabolic dysfunction-associated steatohepatitis.